Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 421 to 430 of 2450 total matches.
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
or motion sickness,
female sex, nonsmoking status, age ...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Ofatumumab (Kesimpta) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
progressive MS, was the first.1 An IV
formulation of ofatumumab (Arzerra) has been
available for treatment ...
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has...
An EUA for Casirivimab and Imdevimab for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
1. High-Risk Conditions for COVID-19 Outpatients1
▶ Age ≥65 years
▶ BMI ≥25 kg/m2 (or, in patients ...
The FDA has issued an Emergency Use Authorization
(EUA) for Regeneron's investigational monoclonal
antibodies casirivimab and imdevimab (REGEN-COV)
to be administered together by IV infusion or SC
injection for treatment of mild to moderate COVID-19
in adults and pediatric patients (≥12 years old and
weigh ≥40 kg) who are at high risk of progressing to
severe COVID-19 and/or hospitalization.
An EUA for Baricitinib (Olumiant) for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
in combination with the IV antiviral drug remdesivir
(Veklury).1 Baricitinib has been available for treatment ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly) has been granted an FDA Emergency
Use Authorization (EUA) for treatment of confirmed or
suspected COVID-19 in hospitalized patients ≥2 years
old who require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO); the EUA requires that baricitinib be used
in combination with the IV antiviral drug remdesivir
(Veklury). Baricitinib has been available for treatment
of rheumatoid arthritis since 2018. Remdesivir was
recently approved by the FDA for treatment of COVID-19
in...
Pemigatinib (Pemazyre) for Cholangiocarcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
is given once daily in 21-day treatment cycles (2 weeks
on, 1 week off); one 21-day treatment cycle ...
The oral kinase inhibitor pemigatinib (Pemazyre –
Incyte) has received accelerated approval from
the FDA for treatment of adults with previously
treated, unresectable, locally advanced or metastatic
cholangiocarcinoma with fibroblast growth factor
receptor 2 (FGFR2) fusions or other rearrangements.
Pemigatinib is the first drug to be approved in the US
for this indication.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • Dec 14, 2020 (Issue 1613)
, and maintain normal lung function.1,2 Management of acute exacerbations of asthma in the emergency department ...
The goal of asthma treatment is to control symptoms,
prevent exacerbations, and maintain normal lung
function. Management of acute exacerbations
of asthma in the emergency department is not
discussed here.
Table: Some Inhaled Drugs for Treatment of Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 14, 2020 (Issue 1613)
)
Albuterol – ProAir HFA (Teva)
generic
90 mcg/inh HFA MDI (200 inh/unit3) 1-2 inh q4-6h PRN ≥4 yrs: 1-2 inh ...
View the table: Some Inhaled Drugs for Treatment of Asthma
Table: Correct Use of Inhalers for Asthma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 14, 2020 (Issue 1613)
a click is heard, the inhaler is
ready to use
The dose indicator should count down by 1
Exhale fully ...
View the table: Correct Use of Inhalers for Asthma
Remdesivir (Veklury) for COVID-19
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
Remdesivir (Veklury) for COVID-19
Table 1. Pharmacology Class Antiviral drug Formulations 100 mg ...
The FDA has approved the antiviral drug remdesivir
(Veklury – Gilead) for IV treatment of COVID-19 in
hospitalized patients who are ≥12 years old and weigh
≥40 kg. Hospitalized children who are <12 years old
or weigh <40 kg can receive remdesivir through an
Emergency Use Authorization (EUA). Remdesivir is
the first drug to be approved in the US for treatment
of COVID-19.
In Brief: New Meningococcal Serogroup B Vaccination Recommendations
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
on Immunization Practices
(ACIP) has issued new recommendations for meningococcal
vaccination.1 Booster ...
The Advisory Committee on Immunization Practices
(ACIP) has issued new recommendations for meningococcal
vaccination. Booster vaccination against
Neisseria meningitidis serogroup B (MenB) is
now recommended in persons at increased risk
for meningococcal disease (see Table 1). MenB
booster doses were not recommended previously for
any population.